US needs to look differently at public health preparedness, says former FDA commissioner Gottlieb

Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities
The ongoing coronavirus pandemic means the US will need to look at public health preparedness through the lens of national security and treat it on par with other kinds of national security threats, according to former US Food and Drug Administration Commissioner, Dr Scott Gottlieb on Tuesday.
Speaking at the hybrid CPHI North America event, Gottlieb said the pandemic had changed the course of history, reset the global order in many significant ways from a geopolitical standpoint, cost trillions of dollars and superseded all other national priorities for more than a year.
“We’re seeing the outsized impact that pathogens and pandemics can have and it means we have to reset how we look at these kinds of risks,” he told delegates.
Outlining the practical measures to tackle future healthcare crises, Gottlieb said the US needs to build different capacities.
“We clearly didn’t have the capacities we thought we had and that we certainty needed,” he said.
He said that the after US’ pandemic planning in 2003, which was focused on concern around H5N1 flu, the country invested in building out certain capacities such as cell-based manufacturing facilities for vaccines, as well as stockpiles and antivirals.
“What happened over time was those efforts atrophied and we didn’t continue to invest in keeping them ready,” he said. “We had this idea that we would create a warm base of preparedness when really what we needed was a hot base of preparedness. You can’t build a vaccine manufacturing plant and mothball it. You really need to be operating these things at scale; in part, because you need to be able to make continuing investments to keep facilities up to date and in part because the only way you can retain personnel to run these kinds of facilities and be ready to scale them up in the event of an emergency is to be operating them.”
He described the country’s prior focus on flu as a mistake: “Even after SARS and MERS came along and it was apparent that coronaviruses were on the march and represented a different kind of threat, we never pivoted our thinking; we never invested in broader capacities that looked beyond flu.”
To register for our four-week hybrid event, CPHI North America and to watch the full webinar on demand, click here.

Related News
-
News CPHI North America Anniversary Ball – celebrating The Art of Pharma
This year marks the 5th anniversary of CPHI North America regional events. To celebrate this remarkable achievement, the CPHI show team hosted The Art of Pharma Anniversary Ball at the illustrious Philadelphia Museum of Art, with a keynote speech from ... -
News Biogen receives accelerated approval for first-of-its-kind ALS treatment
Biogen has announced that they have received approval from the US FDA for the amyotrophic lateral sclerosis (ALS) treatment, QALSODY™ (tofersen). This is the first approval of a treatment that targets a genetic cause of ALS. -
News To recruit or to retain - where is the pharma talent going?
Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. -
News Navigating the North American pharmaceutical regulatory landscape – CPHI North America 2023 preview
As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape. -
News Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses. -
News Samsung Biologics invests in new plant to expand Bio Campus
Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties. -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Pfizer acquires Seagen to become the leading innovator in cancer therapy
Pfizer makes a bold move in the acquisition of innovative cancer therapy biotechnology company Seagen, the move means the doubling of their pipeline of early-stage therapeutics and gaining four leading ADC therapies.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance